Summary
55.37 -1.25(-2.21%)01/16/2026
Bristol-Myers Squibb Company (BMY)
BMY reported last earnings on 2025-10-30 after the market. An EPS of $1.63 was observed compared to an estimated EPS of $1.52, resulting in a surprise value of $0.11. A revenue of $12,222 million was observed compared to an estimated revenue of $11,850 million, resulting in a surprise value of $372 Million.
Bristol-Myers Squibb Company (BMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -2.21 | 2.60 | 14.56 | 25.61 | 19.49 | -0.55 | 8.69 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | A- |
| Recommended Rating | Buy |
| DCF | Strong Buy |
| ROE | Strong Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Neutral |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 55.37 | |
| Open | 56.44 | |
| High | 56.56 | |
| Low | 55.11 | |
| Volume | 8,802,246 | |
| Change | -1.25 | |
| Change % | -2.21 | |
| Avg Volume (20 Days) | 14,421,784 | |
| Volume/Avg Volume (20 Days) Ratio | 0.61 | |
| 52 Week Range | 42.37 - 60.99 | |
| Price vs 52 Week High | -9.22% | |
| Price vs 52 Week Low | 30.67% | |
| Range | 0.57 | |
| Gap Up/Down | -0.38 | |
Profitibility | ||
| Market Capitalization (Mln) | 95,528 | |
| Revenue per share | 23.5696 | |
| Net Income per share | 2.9633 | |
| Dividend Yield | 0.0451 | |
| Dividend Share | 249.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 18.6484 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
01/19 08:20 EST - marketbeat.com
2 Buffett Stocks to Load Up On—And 1 to Ditch
Warren Buffett made some substantial changes to the Berkshire Hathaway Inc. NYSE: BRK.B portfolio in the first quarters of 2025, including selling off some $4 billion in Apple Inc. NASDAQ: AAPL shares in order to amass a major cash and Treasuries reserve.
2 Buffett Stocks to Load Up On—And 1 to Ditch
Warren Buffett made some substantial changes to the Berkshire Hathaway Inc. NYSE: BRK.B portfolio in the first quarters of 2025, including selling off some $4 billion in Apple Inc. NASDAQ: AAPL shares in order to amass a major cash and Treasuries reserve.
01/18 02:24 EST - defenseworld.net
Bristol Myers Squibb Company (NYSE:BMY) Given Average Recommendation of “Hold” by Brokerages
Shares of Bristol Myers Squibb Company (NYSE: BMY - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty-one analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating...
Bristol Myers Squibb Company (NYSE:BMY) Given Average Recommendation of “Hold” by Brokerages
Shares of Bristol Myers Squibb Company (NYSE: BMY - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty-one analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating...
01/16 18:46 EST - zacks.com
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $55.26, indicating a -2.4% shift from the previous trading day.
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $55.26, indicating a -2.4% shift from the previous trading day.
01/16 05:00 EST - defenseworld.net
Bristol Myers Squibb Company $BMY Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund
Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 7.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 510,606 shares of the biopharmaceutical...
Bristol Myers Squibb Company $BMY Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund
Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 7.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 510,606 shares of the biopharmaceutical...
01/15 04:46 EST - defenseworld.net
Conning Inc. Reduces Position in Bristol Myers Squibb Company $BMY
Conning Inc. decreased its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 2.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 701,912 shares of the biopharmaceutical company's stock after selling 14,709 shares during the quarter....
Conning Inc. Reduces Position in Bristol Myers Squibb Company $BMY
Conning Inc. decreased its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 2.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 701,912 shares of the biopharmaceutical company's stock after selling 14,709 shares during the quarter....
01/15 02:16 EST - defenseworld.net
Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk,...
Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk,...
01/14 13:10 EST - zacks.com
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
01/13 10:01 EST - zacks.com
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
01/12 15:45 EST - seekingalpha.com
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01/12 13:35 EST - gurufocus.com
Tempus Shares Jump After Strong Preliminary 2025 Results
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Tempus Shares Jump After Strong Preliminary 2025 Results
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
01/12 06:59 EST - businesswire.com
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
01/12 05:47 EST - feeds.benzinga.com
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01/09 17:35 EST - gurufocus.com
Market Today: Meta taps nuclear; GM books $6B EV charge
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
Market Today: Meta taps nuclear; GM books $6B EV charge
Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax
01/09 10:20 EST - zacks.com
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
01/08 05:04 EST - defenseworld.net
Cerity Partners LLC Has $42.50 Million Holdings in Bristol Myers Squibb Company $BMY
Cerity Partners LLC grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 942,270 shares of the biopharmaceutical company's stock after acquiring an additional...
Cerity Partners LLC Has $42.50 Million Holdings in Bristol Myers Squibb Company $BMY
Cerity Partners LLC grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 942,270 shares of the biopharmaceutical company's stock after acquiring an additional...
01/08 05:04 EST - defenseworld.net
CX Institutional Has $7.48 Million Stock Position in Bristol Myers Squibb Company $BMY
CX Institutional grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,742 shares of the biopharmaceutical company's stock after...
CX Institutional Has $7.48 Million Stock Position in Bristol Myers Squibb Company $BMY
CX Institutional grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,742 shares of the biopharmaceutical company's stock after...
01/07 16:00 EST - fool.com
3 Drug Stocks to Buy at a Discount
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
3 Drug Stocks to Buy at a Discount
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
01/07 09:55 EST - zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
01/06 13:10 EST - zacks.com
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
01/06 09:56 EST - zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Market News
×
Loading news…